News Snapshot:
A leading Chinese vaccine maker said it has commenced phase-3 clinical trials for its COVID-19 vaccine and is planning to recruit 29,000 volunteers across the world. This is China’s first phase-3 efficacy study for a Recombinant subunit COVID-19 vaccine candidate, Anhui Zhifei Longcom Biopharmaceutical, said in a statement on Thursday. Jointly developed by the company and the Institute of Microbiology under the Chinese Academy of Sciences, the vaccine was issued a clinical research permit from the National Medical Products Administration on June 19. The company said the research, which plans to enroll up to 29,000 adults aged 18 and up,...
